Novel GPR40 agonist AS2575959 exhibits glucose metabolism improvement and synergistic effect with sitagliptin on insulin and incretin secretion.

@article{Tanaka2014NovelGA,
  title={Novel GPR40 agonist AS2575959 exhibits glucose metabolism improvement and synergistic effect with sitagliptin on insulin and incretin secretion.},
  author={Hirotsugu Tanaka and Shigeru Yoshida and Hideaki Minoura and Kenji Negoro and Akiyoshi Shimaya and Teruhiko Shimokawa and Masayuki Shibasaki},
  journal={Life sciences},
  year={2014},
  volume={94 2},
  pages={115-21}
}
AIMS GPR40 is a free fatty acid receptor that regulates glucose-dependent insulin secretion at pancreatic β-cells and glucagon-like peptide-1 (GLP-1), one of the major incretins, secretion at the endocrine cells of the gastrointestinal tract. We investigated the synergistic effect of AS2575959, a novel GPR40 agonist, in combination with sitagliptin, a major dipeptidyl peptidase-IV (DPP-IV) inhibitor, on glucose-dependent insulin secretion and GLP-1 secretion. In addition, we investigated the… CONTINUE READING
Highly Cited
This paper has 21 citations. REVIEW CITATIONS